![Novartis Piqray® - First and only treatment specially for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer receives HSA approval[1]](http://en.xfafinance.com/images/defaultpic.gif)
Novartis Piqray® - First and only treatment specially for patients with a PIK3CA muta

Green Future for The Self-Storage Industry: Extra Space Asia Goes The Extra Mile for C

Boeing anticipates Southeast Asia airlines to need 4,400 new airplanes over next 20 ye

The Boutique Hotel Under Gudou Holdings Co., Ltd. Further Expands to Panyu District, G

Medtech Startup GyroGear raises US$4.3m in Phase One of Seed Round led by Taiwan Manuf